Increased incidence of pancreatic carcinoma in rheumatoid arthritis patients receiving leflunomide

Strangfeld A1, Listing J1, Herzer P2, Kekow J3, Rau R2, Schneider M, Zink A1,3
1 German Rheumatism Research Center Berlin, 2 Scientific Advisory Board, München, Magdeburg, Ratingen, Düsseldorf, 3 Charité University Hospital Berlin

Conclusion
Our data suggest that therapy with leflunomide might increase the risk for a pancreatic carcinoma. This safety signal has not been reported before. We cannot rule out that the finding is incidental or that it is caused by an undetected background mechanism which has influenced both the treatment decision and the cancer risk. It therefore needs verification with data from other large, prospective drug safety studies.

Background
The German biologics register RABBIT is an ongoing prospective cohort study that was started in May 2001. It investigates the long-term safety of all biologic agents licensed for the treatment of rheumatoid arthritis (RA). To put the results into perspective, a control cohort with patients treated with conventional DMARDs is observed concurrently. This allows to analyse safety signals not only in patients under treatment with biologics, but also in those treated with conventional DMARDs only.

Patients
RA patients are eligible for the cohort at start of one of the approved biologic agents or at start of a new DMARD therapy after at least one DMARD failure. Regular checks for safety signals are performed in both arms of the cohort. Once enrolled each patient is observed for at least five years. Treatment, clinical status and adverse events are assessed half-yearly at fixed time points of follow-up. If patients are lost to follow-up, their vital status and causes of death are ascertained through queries to the health authorities.

Methods
We calculated age and gender standardized incidence rates (SIR) of pancreatic carcinoma (pCa) based on expected rates available from the German cancer registries in the general population (figure 1). We took the time under observation and the patient case mix into account. To identify possible associations with exposure, we performed a nested case control study.

Results
Data from 5,126 patients with a mean follow-up of 3.1 (±1.6) years were analysed. Drop out rates were below 5% per year.

In total, we observed seven incident pCa during follow-up in RABBIT. Five of these patients were exposed to leflunomide (LEF) as monotherapy (n=2) or in combination with MTX (n=2) or HCQ (n=1). One patient was exposed to adalimumab and one to etanercept. Both of these patients had received LEF before entering the cohort. We took only exposure during the observation in RABBIT into account and therefore considered these patients as unexposed to LEF. In total, 1,970 patients contributing 5,446 patient-years of follow-up were exposed to LEF during observation in the cohort.

Nestled case-control study
Risk factors for pCa include smoking and chronic alcohol abuse. For the nested case-control study we matched each pCa case with 10 cancer-free controls for age, sex, year of study entry and the patient case mix into account. The nested case-control study was based on data of 7,719 patients entered in RABBIT and data of 5,446 patients entered in the nested case-control study. The study started in January 2002. A total of 849 cases of cancer were identified in the nested case-control study. Risk factors for pCa were calculated using conditional logistic regression. We calculated age and gender standardized incidence rates (SIR) of pancreatic carcinoma (pCa) based on expected rates available from the German cancer registries in the general population (2001-2005).

Table 1. Diagnoses at the time of detection of the cancer and the characteristics of the seven patients who developed pancreatic carcinoma.

Cohort studies vs. spontaneous reporting systems
Carefully conducted long-term observational studies capturing all kinds of treatment are of specific value to detect safety signals that would otherwise be overlooked. Since survival time after the diagnosis of pCa is short, the treating rheumatologist may not be aware that the patient died of this disease.

OF NOTE
In our study, four out of the seven patients were drop-outs from the rheumatologic treatment and the diagnosis was obtained only by queries to the treating general practitioner, by hospital discharge letters and by death certificates. Spontaneous reporting systems will inevitably miss those cases.

Supported by a joint, unconditional grant from Abbott, Angen, BMS, essex, Roche, and Wyeth, Germany.

strangfeld@drfz.de